ITMI20111925A1 - COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE TO INCREASE INTESTINAL PERISTALTIC ACTIVITY. - Google Patents
COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE TO INCREASE INTESTINAL PERISTALTIC ACTIVITY. Download PDFInfo
- Publication number
- ITMI20111925A1 ITMI20111925A1 IT001925A ITMI20111925A ITMI20111925A1 IT MI20111925 A1 ITMI20111925 A1 IT MI20111925A1 IT 001925 A IT001925 A IT 001925A IT MI20111925 A ITMI20111925 A IT MI20111925A IT MI20111925 A1 ITMI20111925 A1 IT MI20111925A1
- Authority
- IT
- Italy
- Prior art keywords
- natural fibers
- hyaluronic acid
- increase
- oral use
- water
- Prior art date
Links
- 239000000835 fiber Substances 0.000 title claims description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims description 14
- 229920002674 hyaluronan Polymers 0.000 title claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title claims description 11
- 230000000968 intestinal effect Effects 0.000 title claims description 10
- 230000002572 peristaltic effect Effects 0.000 title description 3
- 210000001072 colon Anatomy 0.000 claims description 6
- 210000003608 fece Anatomy 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 17
- 244000134552 Plantago ovata Species 0.000 description 10
- 235000003421 Plantago ovata Nutrition 0.000 description 10
- 239000009223 Psyllium Substances 0.000 description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 description 10
- 229940070687 psyllium Drugs 0.000 description 10
- 229940010747 sodium hyaluronate Drugs 0.000 description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229940014041 hyaluronate Drugs 0.000 description 6
- 239000009816 fibrolax Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 244000090599 Plantago psyllium Species 0.000 description 4
- 235000010451 Plantago psyllium Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003245 coal Substances 0.000 description 2
- 210000004921 distal colon Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100272807 Rattus norvegicus Btg2 gene Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
"COMPOSIZIONI A BASE DI ACIDO IALURONICO E FIBRE NATURALI PER USO ORALE ATTE AD INCREMENTARE "COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE SUITABLE TO INCREASE
L'ATTIVITÀ' PERISTALTICA INTESTINALE" INTESTINAL PERISTALTIC ACTIVITY "
D E S C R I Z I O N E DESCRIPTION
Il presente trovato ha come oggetto una composizione a base di acido ialuronico e fibre naturali atta a favorire l'attività peristaltica intestinale. The present invention relates to a composition based on hyaluronic acid and natural fibers suitable for promoting intestinal peristaltic activity.
Come à ̈ noto, l’acido ialuronico à ̈ uno dei componenti fondamentali dei tessuti connettivi e delle mucose dell'uomo e degli altri mammiferi, inoltre l'acido Ialuronico à ̈ un polimero con la capacità di sequestrare acqua. As is known, hyaluronic acid is one of the fundamental components of the connective tissues and mucous membranes of man and other mammals, moreover Hyaluronic acid is a polymer with the ability to sequester water.
Compito del presente trovato à ̈ quello di realizzare una associazione di acido Ialuronico e Fibre naturali aventi caratteristiche differenti tra loro, in grado di migliorare l'attività sulla peristalsi intestinale delle stesse fibre. The aim of the present invention is to provide an association of hyaluronic acid and natural fibers having different characteristics, capable of improving the activity of the same fibers on intestinal peristalsis.
Nell'ambito di questo compito, uno scopo del trovato à ̈ quello di realizzare una composizione utilizzabile in diversi settori. Within the scope of this aim, an object of the invention is to provide a composition that can be used in various sectors.
Questo ed altri scopi, che meglio appariranno evidenziati in seguito, sono raggiunti da una composizione costituita dall'asso-ciazione di acido ialuronico con una o più fibre. This and other purposes, which will appear more clearly in the following, are achieved by a composition consisting of the association of hyaluronic acid with one or more fibers.
La combinazione di acido ialuronico con una qualsiasi fibra migliora sensibilmente l'attività delle fibre stesse. The combination of hyaluronic acid with any fiber significantly improves the activity of the fibers themselves.
Questo evidente miglioramento si ottiene utilizzando l'acido ialuronico sia ad alto che a basso peso molecolare. This evident improvement is obtained by using both high and low molecular weight hyaluronic acid.
Nel caso di basso peso molecolare l'attività à ̈ ancora più spiccata in quanto l'acido Ialuronico depolimerizza più rapidamente richiamando più acqua. In the case of low molecular weight, the activity is even more marked as the hyaluronic acid depolymerizes more rapidly, drawing in more water.
L'efficacia dell'associazione di acido ialuronico e fibre naturali à ̈ stata positivamente valutata in relazione al seguente esempio sperimentale che riguarda la valutazione dell'efficacia di diverse preparazioni di fibre naturali più ialuronato di sodio, le fibre naturali utilizzate nello studio sperimentale sono le stesse presenti nei prodotti commerciali seguenti: Fibrolax, Psyllium, Dimalosio, Dualfibre e Benefibra. Il disegno sperimentale prevedeva la valutazione di tre differenti attività correlate utilizzando topi e ratti: The efficacy of the association of hyaluronic acid and natural fibers has been positively evaluated in relation to the following experimental example which concerns the evaluation of the efficacy of different preparations of natural fibers plus sodium hyaluronate, the natural fibers used in the experimental study are the same present in the following commercial products: Fibrolax, Psyllium, Dimalosio, Dualfibre and Benefibra. The experimental design involved the evaluation of three different related activities using mice and rats:
1 - Transiti gastrointestinali 1 - Gastrointestinal transit
2 - Propulsione del Colon 2 - Propulsion of the Colon
3 - Valutazione della quantità di feci 3 - Evaluation of the quantity of feces
1 - Transiti Gastrointestinali 1 - Gastrointestinal Transits
Nella Tabella 1 à ̈ osservabile come la co-somministrazione per gavaggio nel topo della preparazione di semi psillio ed acqua nella quantità di 0.3 ml/topo, induca un incremento della dose dipendente del transito intestinale. In Table 1 it is possible to observe how the co-administration by gavage in mice of the preparation of psyllium seeds and water in the quantity of 0.3 ml / mouse induces an increase in the dose dependent on intestinal transit.
Si osserva infatti un incremento percentuale che passa da 19.7 (Psillio 100 mg/kg acqua) a 25.8 mg/kg p.o. (Psillio 200 acqua). In fact, a percentage increase is observed which goes from 19.7 (Psyllium 100 mg / kg water) to 25.8 mg / kg p.o. (Psyllium 200 water).
Non à ̈ stato ritenuto opportuno aumentare la dose di Psillio in quanto a 400 mg/kg p.o., sempre in presenza di acqua, si osserva la fuoriuscita di feci quasi liquide. It was not considered appropriate to increase the dose of Psyllium as to 400 mg / kg p.o., always in the presence of water, the leakage of almost liquid stools is observed.
L'aggiunta di acqua ha permesso, a parità di dose della preparazione di psillio, un incremento percentuale del transito intestinale da 8.2 a 19.7. The addition of water allowed, for the same dose of the psyllium preparation, a percentage increase in intestinal transit from 8.2 to 19.7.
La somministrazione di ialuronato sodico acqua a 10 e 30 mg/kg p.o., incrementa ulteriormente i transiti intestinali rispettivamente del 15.5 e del 18.4%. The administration of sodium hyaluronate water at 10 and 30 mg / kg p.o., further increases intestinal transits by 15.5 and 18.4% respectively.
Se alla dose di 10 mg/kg p.o. viene associata la preparazione di semi di psillio 100 e 200 mg/kg p.o., si raggiunge un aumento del 24.6% e del 36.5%. If at a dose of 10 mg / kg p.o. the preparation of psyllium seeds 100 and 200 mg / kg p.o. is associated, an increase of 24.6% and 36.5% is achieved.
Infine, l'associazione di semi di psillio 200 mg/kg p.o. con ialuronato 30 mg/kg p.o. ed acqua, induce un aumento del transito intestinale pari al 44.3%. Finally, the association of psyllium seeds 200 mg / kg p.o. with hyaluronate 30 mg / kg p.o. and water, induces an increase in intestinal transit equal to 44.3%.
Le preparazioni prese come riferimento di Fibrolax e Dimalosio, alla dose di 200 mg/kg p.o. acqua, causano un incremento percentuale dei transiti rispettivamente del 22.0 ed 16.7. The preparations taken as reference of Fibrolax and Dimalose, at a dose of 200 mg / kg p.o. water, cause a percentage increase in transits of 22.0 and 16.7 respectively.
Se ad entrambe viene unito ialuronato sodico 30 mg/kg p.o. gli incrementi passano a 30.5 e 26.5%. If both sodium hyaluronate is combined with 30 mg / kg p.o. the increases pass to 30.5 and 26.5%.
Le altre due preparazioni di riferimento, essendo fluide, sono state somministrate al massimo volume iniettabile pari a 10 ml/kg p.o., e tutte e due hanno indotto, in presenza di ialuronato di sodio, un aumento dei transiti di 15.0 e 29.4 rispetto a valori ottenuti in assenza di ialuronato che erano di 10.3 e 21.6. The other two reference preparations, being fluid, were administered at the maximum injection volume equal to 10 ml / kg p.o., and both induced, in the presence of sodium hyaluronate, an increase in transits of 15.0 and 29.4 compared to values obtained in the absence of hyaluronate which were 10.3 and 21.6.
L'esperimento à ̈ stato condotto seguendo il metodo di Schulz et al (NS Arch. Pharmacol. 308:255-260, 1979) utilizzando un pasto di carbone. The experiment was conducted following the method of Schulz et al (NS Arch. Pharmacol. 308: 255-260, 1979) using a coal meal.
Ai topi a digiuno da 24 ore con libero accesso all'acqua à ̈ stata somministrata per gavaggio una sospensione 1 ,5 mi di 20% (peso/volume) di carbone in una soluzione di gomma arabica al 5% (peso/volume). Mice fasted for 24 hours with free access to water were given by gavage a 1.5 ml suspension of 20% (w / v) of charcoal in a 5% (w / v) gum arabic solution.
Dieci minuti dopo aver ricevuto un pasto di carbone i topi sono stati sacrificati e l'intestino rimosso in blocco. Ten minutes after receiving a charcoal meal, the mice were sacrificed and the intestines removed en bloc.
Il transito nell'intestino tenue à ̈ stato calcolato per ciascun topo come il rapporto tra la distanza attraversata dal pasto di carbone e la lunghezza totale dell'intestino stesso. Transit in the small intestine was calculated for each mouse as the ratio between the distance crossed by the coal meal and the total length of the intestine itself.
I dati sono espressi come percentuale di transito nei trattati rispetto ai controlli che sono stati considerati come 100. The data are expressed as a percentage of transit in the treaties compared to the controls which were considered as 100.
La somministrazione delle preparazioni à ̈ avvenuta 30 minuti prima del sacrificio dell'animale. The administration of the preparations took place 30 minutes before the sacrifice of the animal.
2 - Propulsione del colon 2 - Propulsion of the colon
La Tabella 2 mostra come la preparazione di semi di psillio + acqua riesce ad incrementare in modo statisticamente significativo l'attività propulsiva del colon di ratto alla dose di 200 mg/kg p.o. Table 2 shows how the preparation of psyllium seeds + water is able to statistically significantly increase the propulsive activity of the rat colon at a dose of 200 mg / kg p.o.
La dose di 100 mg/kg p.o. Ã ̈ praticamente priva di efficacia. The dose of 100 mg / kg p.o. It is practically ineffective.
In questo modello, analogamente al precedente, lo ialuronato sodico in presenza di acqua riduce in modo dosedipendente il tempo di espulsione di una perlina di vetro. In this model, similar to the previous one, sodium hyaluronate in the presence of water reduces the expulsion time of a glass bead in a dose-dependent manner.
L'attività à ̈ già significativa alla dose di 10 mg7kg p.o. e diviene più evidente alla dose tre volte maggiore. The activity is already significant at the dose of 10 mg7kg p.o. and becomes more evident at three times the dose.
Quando alla preparazione di psillio (100 e 200 mg/kg p.o.) acqua viene associato ialuronato di sodio (10-30 mg/kg p.o.), la riduzione dei tempi di espulsione risulta essere sempre ulteriormente incrementa. When sodium hyaluronate (10-30 mg / kg p.o.) is combined with the preparation of psyllium (100 and 200 mg / kg p.o.), the reduction in expulsion times is always further increased.
Per Fibrolax, Dimalosio, Benefibra e Dualfibre, sempre in presenza di acqua, si assiste ad un effetto maggiore in conseguenza all'associazione con ialuronato. For Fibrolax, Dimalosio, Benefibra and Dualfibre, always in the presence of water, there is a greater effect as a consequence of the association with hyaluronate.
La propulsione del colon distale à ̈ stata misurata in accordo al metodo di Raffa et al. (Life Sci., 41 :2229-34, 1987) e di Lopez (Dig Dis. Sci., 29:551 ,1984). Propulsion of the distal colon was measured according to the method of Raffa et al. (Life Sci., 41: 2229-34, 1987) and by Lopez (Dig Dis. Sci., 29: 551, 1984).
30 minuti dopo la somministrazione delle preparazioni à ̈ stata inserita nel colon distale di ciascun ratto a 3 cm dall'ano una perlina di vetro di 5 mm di diametro. 30 minutes after administration of the preparations, a 5 mm diameter glass bead was inserted into the distal colon of each rat 3 cm from the anus.
Il parametro preso come riferimento à ̈ stato il tempo impiegato da ciascun ratto nell'espellere la perlina di vetro. The benchmark was the time it took each rat to eject the glass bead.
Minore à ̈ il tempo di espulsione, più elevata à ̈ la propulsione colonica. The shorter the expulsion time, the higher the farmhouse propulsion.
3 - Valutazione della quantità di feci 3 - Evaluation of the quantity of feces
In Tabella 3 Ã ̈ possibile osservare l'aumento del numero di pellet espulse dal ratto dopo trattamento con la preparazione di psillio in esame acqua alla dose di 100 e 200 mg/kg p.o. In Table 3 it is possible to observe the increase in the number of pellets expelled by the rat after treatment with the preparation of psyllium in water test at a dose of 100 and 200 mg / kg p.o.
Anche lo ialuronato sodico, in presenza di acqua, di per sé provoca l'espulsione di feci. Even sodium hyaluronate, in the presence of water, by itself causes the expulsion of faeces.
L'effetto diviene assai più marcato se la preparazione di psillio alle dosi (100 e 200 mg/kg p.o.) viene associata allo ialuronato sodico (10 e 30 mg/kg p.o.). The effect becomes much more marked if the psyllium preparation at doses (100 and 200 mg / kg p.o.) is combined with sodium hyaluronate (10 and 30 mg / kg p.o.).
In particolare, la combinazione Psillio 200 mg/kg p.o. e ialuronato 30 mg/kg p.o. in presenza di acqua à ̈ risultata capace di provocare la fuoriuscita di 6 pellets nell'ambito dei 60 minuti di osservazione. In particular, the combination Psyllium 200 mg / kg p.o. and hyaluronate 30 mg / kg p.o. in the presence of water it was found to be capable of causing the release of 6 pellets within the 60 minutes of observation.
Per le preparazioni di Fibrolax, Dimalosio, Benefibra e Dualfibre, alle dosi riportate in Tabella 3, si osserva l'azione potenziente esercitata dallo ialuronato che provoca un incremento del numero di pellet espulse pari ad un doppio nel caso di Fibrolax, Dimalosio, e Dualfibre e del 30% per Benefibra. For the preparations of Fibrolax, Dimalosio, Benefibra and Dualfibre, at the doses shown in Table 3, the potentiating action exerted by the hyaluronate is observed which causes an increase in the number of pellets expelled equal to a double in the case of Fibrolax, Dimalosio, and Dualfibre and 30% for Benefibra.
L'effetto esplicato dalle preparazioni di controllo à ̈ comunque inferiore a quella di psillio acqua ialuronato. The effect of the control preparations is however lower than that of psyllium water hyaluronate.
L'espulsione delle feci à ̈ stata monitorata per ciascun ratto a partire da 1 ora dopo la somministrazione delle preparazioni (Martinez e Taché, Brain Res. 893: 29-35, 2001). Stool expulsion was monitored for each rat starting 1 hour after administration of the preparations (Martinez and Tachà ©, Brain Res. 893: 29-35, 2001).
Conclusioni. Conclusions.
Dai dati ottenuti nel presente esempio si evince che l'associazione tra le differenti Fibre naturali ed ialuronato sodico, in presenza di acqua, induce nel ratto un incremento del transito intestinale e dell'attività propulsiva del colon significativamente superiore a quella presentata da preparati costituiti da sole Fibre acqua. From the data obtained in the present example it can be seen that the association between the different natural fibers and sodium hyaluronate, in the presence of water, induces in the rat an increase in intestinal transit and in the propulsive activity of the colon significantly higher than that presented by preparations consisting of sun Fiber water.
L'aggiunta di ialuronato sodico à ̈ quindi capace di incrementare notevolmente l'efficacia farmacologica dei preparati attualmente in commercio a base di fibre naturali, migliorando tutti i tre parametri valutati che qui riassumiamo: The addition of sodium hyaluronate is therefore capable of significantly increasing the pharmacological efficacy of the preparations currently on the market based on natural fibers, improving all the three evaluated parameters that we summarize here:
Transito gastrointestinale, proulsione del colon e quantità delle feci. Gastrointestinal transit, colon projection and stool quantity.
Si à ̈ in pratica constatato che il trovato raggiunge il compito e gli scopi prefissati. In practice it has been found that the invention achieves the intended aim and objects.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001925A ITMI20111925A1 (en) | 2011-10-25 | 2011-10-25 | COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE TO INCREASE INTESTINAL PERISTALTIC ACTIVITY. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001925A ITMI20111925A1 (en) | 2011-10-25 | 2011-10-25 | COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE TO INCREASE INTESTINAL PERISTALTIC ACTIVITY. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20111925A1 true ITMI20111925A1 (en) | 2013-04-26 |
Family
ID=45464703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT001925A ITMI20111925A1 (en) | 2011-10-25 | 2011-10-25 | COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE TO INCREASE INTESTINAL PERISTALTIC ACTIVITY. |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITMI20111925A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003012537A (en) * | 2001-07-03 | 2003-01-15 | Q'sai Co Ltd | Constipation-improving agent |
| US20050084518A1 (en) * | 2003-10-20 | 2005-04-21 | Medicaraise | Health food containing hyaluronic acid and dermatan sulfate |
| WO2008080809A2 (en) * | 2006-12-29 | 2008-07-10 | Madaus, S.A. | Pharmaceutical composition containing psyllium and senna |
| WO2008141368A1 (en) * | 2007-05-17 | 2008-11-27 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
| WO2008152015A1 (en) * | 2007-06-15 | 2008-12-18 | Masterfarm, S.L. | Composition for the improvement of functional difficulties due to articular cartilage disorders |
-
2011
- 2011-10-25 IT IT001925A patent/ITMI20111925A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003012537A (en) * | 2001-07-03 | 2003-01-15 | Q'sai Co Ltd | Constipation-improving agent |
| US20050084518A1 (en) * | 2003-10-20 | 2005-04-21 | Medicaraise | Health food containing hyaluronic acid and dermatan sulfate |
| WO2008080809A2 (en) * | 2006-12-29 | 2008-07-10 | Madaus, S.A. | Pharmaceutical composition containing psyllium and senna |
| WO2008141368A1 (en) * | 2007-05-17 | 2008-11-27 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
| WO2008152015A1 (en) * | 2007-06-15 | 2008-12-18 | Masterfarm, S.L. | Composition for the improvement of functional difficulties due to articular cartilage disorders |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Derwent World Patents Index; AN 2003-508524, XP002672821 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| BR112013022495A2 (en) | tapentadol aqueous pharmaceutical formulation for oral administration | |
| UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
| ES2355109T3 (en) | MIXING OF A VAINILLOID RECEIVER AGONIST WITH AN INHIBITING SUBSTANCE OF THE NERVOUS REGENERATION, ITS USE FOR THE MANUFACTURE OF AN ANALGESIC AND PROCEDURE OF APPLICATION OF THIS DRUG. | |
| NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
| BR112014016085A8 (en) | Enhanced compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
| CU20170161A7 (en) | ORODISPERSABLE DOSAGE UNIT CONTAINING A STETROL COMPONENT | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| PE20081106A1 (en) | CAPECITABIN PEDIATRIC TABLETS | |
| HRP20180061T1 (en) | Indolecarbonitriles as selective androgen receptor modulators | |
| BR112013028776A2 (en) | kit and use of a pharmaceutical or nutraceutical composition | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2012524112A5 (en) | ||
| EA201300539A1 (en) | HARDWARE | |
| AR062659A1 (en) | COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE | |
| JP2013534228A5 (en) | ||
| JP2016512247A5 (en) | ||
| RU2020120156A (en) | TREATMENT AND LOSS OF BONE TISSUE CAUSED BY ANDROGENIC DEPRIVATION THERAPY USING CIS-CLOMIFEN | |
| BR112012022209A2 (en) | pharmaceutical compositions comprising monoterpenes | |
| ITMI20111925A1 (en) | COMPOSITIONS BASED ON HYALURONIC ACID AND NATURAL FIBERS FOR ORAL USE TO INCREASE INTESTINAL PERISTALTIC ACTIVITY. | |
| Frisbie | Principals of treatment of joint disease | |
| BRPI0410374A (en) | pharmaceutical composition comprising valsartan | |
| Zelada et al. | Viscosupplementation in patients with hemophilic arthropathy | |
| JP6100510B2 (en) | Anti-cold medicine |